Immunohistochemical expression of cyclin D1, p16Ink4a, p21 WAF1, and Ki-67 correlates with the severity of cervical neoplasia

International Journal of Gynecological Pathology

Volumn 32, Issue 5, 2013, Pages 501-508

  Portari, Elyzabeth A ^a   Russomano, Fábio B ^d   De Camargo, Maria J ^d   Machado Gayer, Carlos R ^b   Da Rocha Guillobel, Heloísa C ^a   Santos Rebouças, Cíntia B ^c   Brito Macedo, Jacyara M ^b  

^a Department of Pathology ^*  (United States)

^b STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c Levy Economics Institute   (United States)

^d INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

cell cycle biomarkers; cervical neoplasia; human papillomavirus; tissue microarray

Indexed keywords

CYCLIN D1; KI 67 ANTIGEN; PROTEIN P16; PROTEIN P21; CCND1 PROTEIN, HUMAN; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; P16 PROTEIN, HUMAN; PROTEIN P53; TUMOR MARKER; TUMOR PROTEIN;

ADENOCARCINOMA; ARTICLE; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; THICKNESS; TISSUE MICROARRAY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA; BRAZIL; CARCINOGENESIS; CARCINOMA IN SITU; CELL CYCLE; METABOLISM; PAPILLOMA VIRUS; PAPILLOMAVIRUS INFECTION; PATHOLOGY; PHYSIOLOGY; PRECANCER; UTERINE CERVIX; UTERINE CERVIX TUMOR;

BRAZIL; CARCINOGENESIS; CARCINOMA IN SITU; CELL CYCLE; CERVIX UTERI; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P21; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; NEOPLASM PROTEINS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PRECANCEROUS CONDITIONS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; UTERINE CERVICAL NEOPLASMS;

EID: 84883464945     PISSN: 02771691     EISSN: 15387151     Source Type: Journal    
DOI: 10.1097/PGP.0b013e31826f5cf6     Document Type: Article

References (48)

1. Castellsagué X, De Sanjosé S, Aguado T, et al. HPV and cervical cancer in the world 2007 report. Vaccine 2007;25S:C1-26.
2. World Health Organization (WHO). HPV Information Centre. Human papillomavirus and related cancer, 2010. Available at: http://apps.who.int/ hpvcentre/statistics/dynamic/ico/country-pdf/XWX.pdf?CFID=6769957&CFTOKEN= 22023753. Accessed May 25, 2012.
3. Baak JPA, Kruse AJ, Robboy SJ, et al. Dynamic behavioural interpretation of cervical intraepithelial neoplasia with molecular biomarkers. J Clin Pathol 2006;59:1017-28.
4. Doobar J. Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci 2006;110:525-41.
5. Zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002;2:342-50.
6. Moody CA, Laimins LA. Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer 2010;10:550-60.
7. Bahnassy AA, Zekri AR, Saleh M, et al. The possible role of cell cycle regulators in multistep process of HPV-associated cervical carcinoma. BMC Clin Pathol 2007;7:4-15.
8. Skomedal H, Kristensen GB, Lie AK, et al. Aberrant expression of the cell cycle associated proteins TP53, MDM2, p21, p27, cdk4, cyclin D1, Rb and EGFR in cervical carcinomas. Gynecol Oncol 1999;73:223-8.
9. Conesa-Zamora P, Doménech-Peris A, Orantes-Casado FJ, et al. Effect of human papillomavirus on cell cycle-related proteins p16, Ki-67, Cyclin D1, p53, and ProEx C in precursor lesions of cervical carcinoma: a tissue microarray study. Am J Clin Pathol 2009;132:378-90.
10. Pires ARC, Andreiuolo FM, de Souza SR. TMA for all: a new method for the construction of tissue microarrays without recipient paraffin block using custom-built needles. Diagn Pathol 2006;1:14. Available at: http://www. diagnosticpathology.org/content/1/1/14.
11. Badr RE, Walts AE, Chung F, et al. BD ProEx C: a sensitive and specific marker of HPV-associated squamous lesions of the cervix. Am J Surg Pathol 2008;32:899-906.
12. Khunamornpong S, Siriaunkgul S, Manusirivithaya S, et al. Prognostic value of p53 expression in early stage cervical carcinoma treated by surgery. Asian Pacific J Cancer Prev 2008;9:48-52.
13. Kim YT, Zhao M. Aberrant cell cycle regulation in cervical carcinoma. Yonsei Med J 2005;46:597-613.
14. Trimble CL. Naturally occurring systemic immune response to HPV antigens do not predict regression of CIN2/3. Cancer Immunol Immunother 2010;59:799-803.
15. Ovestad IT, Gudlaugsson E, Skaland I, et al. The impact of epithelial biomarkers, local immune response and human papillomavirus genotype in the regression of cervical intraepithelial neoplasia grades 2-3. J Clin Pathol 2011;64:303-7.
16. Galgano MT, Castle PE, Atkins KA, et al. Using biomarkers as objective standards in the diagnosis of cervical biopsies. Am J Surg Pathol 2010;34:1077-87.
17. Vinyuvat S, Karalak A, Suthipintawong C, et al. Interobserver reproducibility in determining p16 overexpression in cervical lesions: use of a combined scoring method. Asian Pacific J Cancer Prev 2008;9:653-7.
18. Bergeron C, Ordi J, Schmidt D, et al. Conjunctive p16 INK4a testing significantly increases accuracy in diagnosing highgrade cervical intraepithelial neoplasia. Am J Clin Pathol 2010;133:395-406.
19. Ozaki S, Zen Y, Masaki I. Biomarker expression in cervical intraepithelial neoplasia: potential progression predictive factors for low-grade lesions. Hum Pathol 2011;42:1007-12.
20. Ordi J, Garcia S, del Pino M, et al. p16INK4A immunostaining identifies occult CIN lesions in HPV-positive women. Int J Gynecol Pathol 2009;28:90-7.
21. Hanprasertpong J, Tungsinmunkong K, Chichareon S, et al. Correlation of p53 and Ki-67 (MIB-1) expressions with clinicopathological features and prognosis of early stage cervical squamous cell carcinomas. J Obstet Gynaecol Res 2010;36:572-80.
22. Huang LW, Lee CC. p16INK4a overexpression predicts lymph node metastasis in cervical carcinomas. J Clin Pathol 2012; 65:117-21.
23. Tsuda H, Hashiguchi Y, Nishimura S, et al. Relationship between HPV typing and abnormality of G1 cell cycle regulators in cervical neoplasm. Gynecol Oncol 2003;91: 476-85.
24. Graflund M, Sorbe B, Karlsson M. Immunohistochemical expression of p53, bcl-2, and p21(WAF1/CIP1) in early cervical carcinoma: correlation with clinical outcome. Int J Gynecol Cancer 2002;12:290-8.
25. Ikuta A, Saito J, Mizokami T, et al. Correlation p53 expression and human papillomavirus deoxyribonucleic acid with clinical outcome in early uterine cervical carcinoma. Cancer Detect Prev 2005;29:528-36.
26. Lu H, Gan M, Zhang G, et al. Expression of surviving, caspase-3 and p53 in cervical cancer assessed by tissue microarray: correlation with clinicopathology and prognosis. Eur J Gynaec Oncol 2010;31:662-6.
27. Baak JPA, Kruse AJ, Garland SM, et al. Combined p53 and retinoblastoma protein detection identifies persistent and regressive cervical high-grade squamous intraepithelial lesions. Am J Surg Pathol 2005;29:1062-66.
28. Nichols GE, Williams ME, Gaffey MJ, et al. Cyclin D1 gene expression in human cervical neoplasia. Mod Pathol 1996;9:418-25.
29. Little L, Stewart CJR. Cyclin D1 immunoreactivity in normal endocervix and diagnostic value in reactive and neoplastic endocervical lesions. Mod Pathol 2010;23:611-8.
30. Cho NH, Kim YT, Kim JW. Alteration of cell cycle in cervical tumor associated with human papillomavirus: cyclin-dependent kinase inhibitors. Yonsei Med J 2002;43:722-8.
31. Bae DS, Cho SB, Kim YJ, et al. Aberrant expression of cyclin D1 is associated with poor prognosis in early stage cervical cancer of the uterus. Gynecol Oncol 2001;81:341-7.
32. Vijayalakshmi N, Selvaluxmi G, Majhi U, et al. Alterations found in p16/Rb/cyclin D1 pathway in the dysplastic and malignant cervical epithelium. Oncol Res 2007;16:527-33.
33. Huang LW, Chou YY, Chao SL, et al. p53 and p21 expression in precancerous lesions and carcinomas of the uterine cervix: overexpression of p53 predicts poor disease outcome. Gynecol Oncol 2001;83:348-54.
34. Lie AK, Skarsvag S, Skomedal H, et al. Expression of p53, MDM2, and p21 proteins in high-grade cervical intraepithelial neoplasia and relationship to human papillomavirus infection. Int J Gynecol Pathol 1999;18:5-11.
35. Pinto AP, Degen M, Villa LL, et al. Immunomarkers in gynecologic cytology: the search for the ideal 'biomolecular Papanicolaou test'. Acta Cytol 2012;56:109-21.
36. Tosun G, Sendag F, Zeybek B, et al. Immunohistochemical expressions of p16 and p53 proteins in cervical intraepithelial neoplasia and in benign cervical tissue. Eur J Gynaec Oncol 2010;31:627-31.
37. Klaes R, Benner A, Friedrich T, et al. p16INK4A immunohistochemistry improves interobserver agreement in the diagnosis of cervical intraepithelial neoplasia. Am J Surg Pathol 2002;26: 1389-99.
38. Klaes R, Friedrich T, Spitkovsky D, et al. Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer 2001;92:276-84.
39. Wang JL, Zheng BY, Li XD, et al. Predictive significance of the alterations of p16INK4A, p14ARF, p53, and proliferating cell nuclear antigen expression in the progression of cervical cancer. Clin Cancer Res 2004;10:2407-14.
40. Horn LC, Reichert A, Oster A, et al. Immunostaining for p16INK4a used as a conjunctive tool improves interobserver agreement of the histologic diagnosis of cervical intraepithelial neoplasia. Am J Surg Pathol 2008;32:502-12.
41. Branca M, Ciotti M, Santini D, et al. p16INK4A expression is related to grade of CIN and high-risk human papillomavirus but does not predict virus clearance after conization or disease outcome. Int J Gynecol Pathol 2004;23:354-65.
42. Hu L, Duo M, He Z, et al. Human papillomavirus genotyping and p16INK4A expression in cervical intraepithelial neoplasia of adolescents. Mod Pathol 2005;18:267-73.
43. Murphy N, Ring M, Killalea AG, et al. p16INK4A as a marker for cervical dyskaryosis: CIN and cGIN in cervical biopsies and ThinPrep smears. J Clin Pathol 2003;56:56-63.
44. Atkins K. p16/Ki-67 dual-stain cytology in the triage of ASCUS and LSIL Papanicolaou cytology. Cancer Cytopathol 2011;119:145-7.
45. Schwarz JK, Lewis JS, Jr Pfeifer J, et al. Prognostic significance of p16 expression in advanced cervical cancer treated with definitive radiotherapy. Int J Radiation Oncol Biol Phys 2012;84:153-7. (In press) http://dx.doi.org/10. 1016/j.ijrobp. 2011.11.032.
46. Kruse AJ, Baak JPA, Helliesen T, et al. Evaluation of MIB-1- positive cell clusters as a diagnostic marker for cervical intraepithelial neoplasia. Am J Surg Pathol 2002;26:1501-7.
47. Niekerk DV, Guillaud M, Matisic J, et al. p16 and MIB1 improve the sensitivity and specificity of the diagnosis of high grade squamous intraepithelial lesions: Methodological issues in a report of 447 biopsies with consensus diagnosis and HPV HCII testing. Gynecol Oncol 2007;107:S233-40.
48. Samarawardana P, Singh M, Shrover KR. Dual stain immunohistochemical localization of p16INK4a and Ki-67: a synergistic approach to identify clinically significant cervical mucosal lesions. Appl Immunohistochem Mol Morphol 2011; 19:514-8.